Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, Optical Coherence | 20 | 2025 | 236 | 2.460 |
Why?
|
| Visual Acuity | 16 | 2025 | 137 | 2.200 |
Why?
|
| Wet Macular Degeneration | 4 | 2025 | 24 | 2.070 |
Why?
|
| Macular Degeneration | 7 | 2025 | 196 | 1.960 |
Why?
|
| Retinal Diseases | 4 | 2024 | 34 | 1.440 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2024 | 83 | 1.400 |
Why?
|
| Macular Edema | 3 | 2024 | 24 | 1.370 |
Why?
|
| Retinal Pigment Epithelium | 4 | 2025 | 35 | 1.160 |
Why?
|
| Geographic Atrophy | 5 | 2025 | 20 | 1.020 |
Why?
|
| Fluorescein Angiography | 10 | 2025 | 63 | 0.990 |
Why?
|
| Intravitreal Injections | 9 | 2025 | 55 | 0.920 |
Why?
|
| Retinal Vasculitis | 2 | 2022 | 9 | 0.890 |
Why?
|
| Ranibizumab | 3 | 2022 | 22 | 0.860 |
Why?
|
| Retinal Vein Occlusion | 1 | 2024 | 18 | 0.800 |
Why?
|
| Hawks | 1 | 2022 | 1 | 0.740 |
Why?
|
| Retinal Dystrophies | 1 | 2021 | 4 | 0.710 |
Why?
|
| Peripherins | 1 | 2021 | 14 | 0.700 |
Why?
|
| Retina | 3 | 2024 | 135 | 0.670 |
Why?
|
| Cysts | 2 | 2013 | 44 | 0.640 |
Why?
|
| Endotamponade | 1 | 2020 | 9 | 0.620 |
Why?
|
| Retinal Perforations | 1 | 2020 | 6 | 0.620 |
Why?
|
| Basement Membrane | 1 | 2020 | 27 | 0.620 |
Why?
|
| Fovea Centralis | 2 | 2023 | 15 | 0.610 |
Why?
|
| Vitrectomy | 1 | 2020 | 34 | 0.600 |
Why?
|
| Diabetic Retinopathy | 2 | 2021 | 60 | 0.590 |
Why?
|
| Vitreous Body | 3 | 2024 | 31 | 0.570 |
Why?
|
| Choroid Neoplasms | 2 | 2016 | 22 | 0.550 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2016 | 234 | 0.520 |
Why?
|
| Laser Coagulation | 3 | 2016 | 16 | 0.520 |
Why?
|
| Humans | 34 | 2025 | 65654 | 0.440 |
Why?
|
| Ectopia Lentis | 1 | 2014 | 1 | 0.440 |
Why?
|
| Aptamers, Nucleotide | 2 | 2025 | 27 | 0.430 |
Why?
|
| Marfan Syndrome | 1 | 2014 | 19 | 0.430 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2014 | 7 | 0.420 |
Why?
|
| Nocardia | 1 | 2014 | 1 | 0.420 |
Why?
|
| Nocardia Infections | 1 | 2014 | 3 | 0.420 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 46 | 0.420 |
Why?
|
| Retinal Drusen | 1 | 2014 | 16 | 0.420 |
Why?
|
| Eye Infections, Bacterial | 1 | 2014 | 11 | 0.410 |
Why?
|
| Endophthalmitis | 1 | 2014 | 16 | 0.410 |
Why?
|
| Eye Injuries | 1 | 2014 | 13 | 0.410 |
Why?
|
| Lasers | 1 | 2014 | 39 | 0.410 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 2496 | 0.410 |
Why?
|
| Blindness | 1 | 2014 | 43 | 0.400 |
Why?
|
| Radiosurgery | 1 | 2014 | 68 | 0.400 |
Why?
|
| Muscle Cramp | 1 | 2013 | 2 | 0.390 |
Why?
|
| POEMS Syndrome | 1 | 2013 | 2 | 0.390 |
Why?
|
| Femoral Neoplasms | 1 | 2013 | 5 | 0.390 |
Why?
|
| Conjunctival Diseases | 1 | 2013 | 3 | 0.390 |
Why?
|
| Strabismus | 1 | 2013 | 2 | 0.390 |
Why?
|
| Polyethylene Glycols | 2 | 2025 | 172 | 0.390 |
Why?
|
| Pigment Epithelium of Eye | 2 | 2015 | 12 | 0.380 |
Why?
|
| Fundus Oculi | 2 | 2025 | 26 | 0.340 |
Why?
|
| Male | 18 | 2025 | 31297 | 0.330 |
Why?
|
| Bevacizumab | 3 | 2024 | 61 | 0.320 |
Why?
|
| Choroidal Neovascularization | 2 | 2023 | 28 | 0.310 |
Why?
|
| Aged | 10 | 2025 | 15090 | 0.290 |
Why?
|
| Female | 18 | 2025 | 34310 | 0.290 |
Why?
|
| Adult | 11 | 2024 | 17511 | 0.280 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2022 | 37 | 0.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 254 | 0.270 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 374 | 0.260 |
Why?
|
| Eye Diseases | 1 | 2008 | 37 | 0.260 |
Why?
|
| Complement Inactivating Agents | 2 | 2025 | 15 | 0.260 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 5657 | 0.240 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2022 | 503 | 0.240 |
Why?
|
| Postoperative Complications | 1 | 2013 | 1335 | 0.230 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1233 | 0.230 |
Why?
|
| Treatment Outcome | 5 | 2025 | 5820 | 0.220 |
Why?
|
| Atrophy | 1 | 2025 | 87 | 0.220 |
Why?
|
| Subretinal Fluid | 2 | 2022 | 3 | 0.210 |
Why?
|
| Amyl Nitrite | 1 | 2024 | 3 | 0.210 |
Why?
|
| Retrospective Studies | 5 | 2025 | 6948 | 0.200 |
Why?
|
| Middle Aged | 9 | 2025 | 18440 | 0.190 |
Why?
|
| Double-Blind Method | 4 | 2025 | 745 | 0.180 |
Why?
|
| Choroid Diseases | 1 | 2021 | 4 | 0.180 |
Why?
|
| Pedigree | 1 | 2021 | 193 | 0.170 |
Why?
|
| Uveitis | 1 | 2021 | 34 | 0.160 |
Why?
|
| Prone Position | 1 | 2020 | 28 | 0.150 |
Why?
|
| Postoperative Period | 1 | 2020 | 130 | 0.150 |
Why?
|
| Osteoma | 1 | 2016 | 1 | 0.120 |
Why?
|
| Posterior Eye Segment | 1 | 2016 | 1 | 0.120 |
Why?
|
| Eye Infections, Viral | 1 | 2016 | 3 | 0.120 |
Why?
|
| Coxsackievirus Infections | 1 | 2016 | 12 | 0.120 |
Why?
|
| Retinal Detachment | 1 | 2016 | 22 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 1662 | 0.110 |
Why?
|
| Varicose Veins | 1 | 2015 | 7 | 0.110 |
Why?
|
| Albinism, Oculocutaneous | 1 | 2015 | 1 | 0.110 |
Why?
|
| Iris Diseases | 1 | 2015 | 2 | 0.110 |
Why?
|
| Venous Pressure | 1 | 2015 | 2 | 0.110 |
Why?
|
| Lenses, Intraocular | 1 | 2015 | 7 | 0.110 |
Why?
|
| Valsalva Maneuver | 1 | 2015 | 11 | 0.110 |
Why?
|
| Retinal Hemorrhage | 1 | 2015 | 7 | 0.110 |
Why?
|
| Retinal Neoplasms | 1 | 2015 | 17 | 0.110 |
Why?
|
| Choroid | 1 | 2015 | 17 | 0.110 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2014 | 3 | 0.110 |
Why?
|
| Macula Lutea | 1 | 2015 | 26 | 0.110 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2014 | 7 | 0.110 |
Why?
|
| Hypopigmentation | 1 | 2015 | 15 | 0.110 |
Why?
|
| Lens, Crystalline | 1 | 2014 | 16 | 0.110 |
Why?
|
| Tuberous Sclerosis | 1 | 2014 | 11 | 0.110 |
Why?
|
| Global Health | 1 | 2016 | 181 | 0.110 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 88 | 0.110 |
Why?
|
| Remission Induction | 1 | 2014 | 149 | 0.100 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 10 | 0.100 |
Why?
|
| Indoles | 1 | 2014 | 112 | 0.100 |
Why?
|
| Mycophenolic Acid | 1 | 2014 | 68 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 133 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 994 | 0.100 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2013 | 5 | 0.100 |
Why?
|
| Phlebography | 1 | 2013 | 45 | 0.100 |
Why?
|
| Exercise Test | 1 | 2015 | 257 | 0.100 |
Why?
|
| Papilledema | 1 | 2013 | 9 | 0.100 |
Why?
|
| Mutation | 1 | 2021 | 2672 | 0.100 |
Why?
|
| Child | 3 | 2014 | 4634 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 552 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 154 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 898 | 0.090 |
Why?
|
| Incidence | 1 | 2016 | 1432 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 367 | 0.090 |
Why?
|
| Vision Disorders | 3 | 2016 | 69 | 0.080 |
Why?
|
| Uveal Neoplasms | 1 | 2009 | 50 | 0.070 |
Why?
|
| Supine Position | 1 | 2008 | 35 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2014 | 2113 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 308 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2730 | 0.060 |
Why?
|
| Melanoma | 1 | 2009 | 334 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 3329 | 0.060 |
Why?
|
| Indocyanine Green | 2 | 2015 | 12 | 0.050 |
Why?
|
| Coloring Agents | 2 | 2015 | 51 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2024 | 33 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 2023 | 23 | 0.050 |
Why?
|
| Animals | 1 | 2022 | 21467 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 2262 | 0.050 |
Why?
|
| Organic Chemicals | 1 | 2023 | 27 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 858 | 0.050 |
Why?
|
| Patient Selection | 1 | 2024 | 484 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 462 | 0.040 |
Why?
|
| Adolescent | 3 | 2016 | 6350 | 0.040 |
Why?
|
| Time Factors | 1 | 2024 | 3777 | 0.030 |
Why?
|
| Retinitis | 1 | 2016 | 6 | 0.030 |
Why?
|
| Miosis | 1 | 2015 | 2 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 72 | 0.030 |
Why?
|
| Melanins | 1 | 2015 | 24 | 0.030 |
Why?
|
| Prednisolone | 1 | 2014 | 11 | 0.030 |
Why?
|
| Ketorolac | 1 | 2014 | 13 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2014 | 17 | 0.030 |
Why?
|
| Acne Vulgaris | 1 | 2014 | 23 | 0.030 |
Why?
|
| Headache | 1 | 2014 | 58 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1195 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 463 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 202 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2014 | 190 | 0.020 |
Why?
|
| Young Adult | 2 | 2016 | 4855 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 1235 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2009 | 9 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2009 | 16 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 21 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2009 | 40 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 2076 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 5466 | 0.010 |
Why?
|